At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 609 enrolled
Drug / intervention
IW-3718 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients With Gastroesophageal Reflux Disease While Receiving Proton Pump Inhibitors
In Brief
A Phase 3 clinical trial evaluating IW-3718, placebo, and 1 other intervention for Gastroesophageal Reflux Disease (GERD). Completed, enrolled 609 participants across 101 sites in 2 countries.
Detailed Summary
The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD), standard dose PPIs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroesophageal Reflux Disease (GERD)
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJun 2018
Enrollment StartSep 2018
Primary CompletionJul 2020
Study CompletionNov 2020
TodayJul 2026
First PostedJun 19, 2018
Enrollment StartSep 6, 2018
Primary CompletionJul 28, 2020
Study CompletionNov 6, 2020
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 8.0 years ago
Interventions
IW-3718drug
oral tablet
placebodrug
oral tablet
Standard-dose PPIs QDdrug
background therapy